260 related articles for article (PubMed ID: 12898466)
21. Insulin-sensitizing effect of rosiglitazone (BRL-49653) by regulation of glucose transporters in muscle and fat of Zucker rats.
Kramer D; Shapiro R; Adler A; Bush E; Rondinone CM
Metabolism; 2001 Nov; 50(11):1294-300. PubMed ID: 11699047
[TBL] [Abstract][Full Text] [Related]
22. Pioglitazone ameliorates tumor necrosis factor-alpha-induced insulin resistance by a mechanism independent of adipogenic activity of peroxisome proliferator--activated receptor-gamma.
Iwata M; Haruta T; Usui I; Takata Y; Takano A; Uno T; Kawahara J; Ueno E; Sasaoka T; Ishibashi O; Kobayashi M
Diabetes; 2001 May; 50(5):1083-92. PubMed ID: 11334412
[TBL] [Abstract][Full Text] [Related]
23. Peroxisome proliferator-activated receptor-gamma ligands inhibit adipocyte 11beta -hydroxysteroid dehydrogenase type 1 expression and activity.
Berger J; Tanen M; Elbrecht A; Hermanowski-Vosatka A; Moller DE; Wright SD; Thieringer R
J Biol Chem; 2001 Apr; 276(16):12629-35. PubMed ID: 11278270
[TBL] [Abstract][Full Text] [Related]
24. Hypoglycemic action of thiazolidinediones/peroxisome proliferator-activated receptor gamma by inhibition of the c-Jun NH2-terminal kinase pathway.
Díaz-Delfín J; Morales M; Caelles C
Diabetes; 2007 Jul; 56(7):1865-71. PubMed ID: 17416798
[TBL] [Abstract][Full Text] [Related]
25. A single element in the phosphoenolpyruvate carboxykinase gene mediates thiazolidinedione action specifically in adipocytes.
Glorian M; Duplus E; Beale EG; Scott DK; Granner DK; Forest C
Biochimie; 2001 Oct; 83(10):933-43. PubMed ID: 11728630
[TBL] [Abstract][Full Text] [Related]
26. A novel selective peroxisome proliferator-activator receptor-gamma modulator-SPPARgammaM5 improves insulin sensitivity with diminished adverse cardiovascular effects.
Chang CH; McNamara LA; Wu MS; Muise ES; Tan Y; Wood HB; Meinke PT; Thompson JR; Doebber TW; Berger JP; McCann ME
Eur J Pharmacol; 2008 Apr; 584(1):192-201. PubMed ID: 18346728
[TBL] [Abstract][Full Text] [Related]
27. Role of skeletal muscle in thiazolidinedione insulin sensitizer (PPARgamma agonist) action.
Zierath JR; Ryder JW; Doebber T; Woods J; Wu M; Ventre J; Li Z; McCrary C; Berger J; Zhang B; Moller DE
Endocrinology; 1998 Dec; 139(12):5034-41. PubMed ID: 9832442
[TBL] [Abstract][Full Text] [Related]
28. MBX-102/JNJ39659100, a novel peroxisome proliferator-activated receptor-ligand with weak transactivation activity retains antidiabetic properties in the absence of weight gain and edema.
Gregoire FM; Zhang F; Clarke HJ; Gustafson TA; Sears DD; Favelyukis S; Lenhard J; Rentzeperis D; Clemens LE; Mu Y; Lavan BE
Mol Endocrinol; 2009 Jul; 23(7):975-88. PubMed ID: 19389808
[TBL] [Abstract][Full Text] [Related]
29. Thiazolidinedione-induced activation of the transcription factor peroxisome proliferator-activated receptor gamma in cells adjacent to the murine skeletal muscle: implications for fibroblast functions.
Löhrke B; Shahi SK; Krüger B; Schmidt P; Renne U; Dietl G
Pflugers Arch; 2000 Jan; 439(3):288-96. PubMed ID: 10650980
[TBL] [Abstract][Full Text] [Related]
30. Peroxisome proliferator-activated receptor gamma thiazolidinedione agonists increase glucose metabolism in astrocytes.
Dello Russo C; Gavrilyuk V; Weinberg G; Almeida A; Bolanos JP; Palmer J; Pelligrino D; Galea E; Feinstein DL
J Biol Chem; 2003 Feb; 278(8):5828-36. PubMed ID: 12486128
[TBL] [Abstract][Full Text] [Related]
31. Synthetic peroxisome proliferator-activated receptor-gamma agonist, rosiglitazone, increases plasma levels of adiponectin in type 2 diabetic patients.
Yang WS; Jeng CY; Wu TJ; Tanaka S; Funahashi T; Matsuzawa Y; Wang JP; Chen CL; Tai TY; Chuang LM
Diabetes Care; 2002 Feb; 25(2):376-80. PubMed ID: 11815513
[TBL] [Abstract][Full Text] [Related]
32. Peroxisome proliferator-activated receptor-gamma in thyroid eye disease: contraindication for thiazolidinedione use?
Starkey K; Heufelder A; Baker G; Joba W; Evans M; Davies S; Ludgate M
J Clin Endocrinol Metab; 2003 Jan; 88(1):55-9. PubMed ID: 12519830
[TBL] [Abstract][Full Text] [Related]
33. Thiazolidinedione exposure increases the expression of uncoupling protein 1 in cultured human preadipocytes.
Digby JE; Montague CT; Sewter CP; Sanders L; Wilkison WO; O'Rahilly S; Prins JB
Diabetes; 1998 Jan; 47(1):138-41. PubMed ID: 9421389
[TBL] [Abstract][Full Text] [Related]
34. Phenylacetic acid derivatives as hPPAR agonists.
Santini C; Berger GD; Han W; Mosley R; MacNaul K; Berger J; Doebber T; Wu M; Moller DE; Tolman RL; Sahoo SP
Bioorg Med Chem Lett; 2003 Apr; 13(7):1277-80. PubMed ID: 12657263
[TBL] [Abstract][Full Text] [Related]
35. Ameliorating effect of FK614, a novel nonthiazolidinedione peroxisome proliferator-activated receptor gamma agonist, on insulin resistance in Zucker fatty rat.
Minoura H; Takeshita S; Yamamoto T; Mabuchi M; Hirosumi J; Takakura S; Kawamura I; Seki J; Manda T; Ita M; Mutoh S
Eur J Pharmacol; 2005 Sep; 519(1-2):182-90. PubMed ID: 16039648
[TBL] [Abstract][Full Text] [Related]
36. MK-0767, a novel dual PPARalpha/gamma agonist, displays robust antihyperglycemic and hypolipidemic activities.
Doebber TW; Kelly LJ; Zhou G; Meurer R; Biswas C; Li Y; Wu MS; Ippolito MC; Chao YS; Wang PR; Wright SD; Moller DE; Berger JP
Biochem Biophys Res Commun; 2004 May; 318(2):323-8. PubMed ID: 15120604
[TBL] [Abstract][Full Text] [Related]
37. A novel N-aryl tyrosine activator of peroxisome proliferator-activated receptor-gamma reverses the diabetic phenotype of the Zucker diabetic fatty rat.
Brown KK; Henke BR; Blanchard SG; Cobb JE; Mook R; Kaldor I; Kliewer SA; Lehmann JM; Lenhard JM; Harrington WW; Novak PJ; Faison W; Binz JG; Hashim MA; Oliver WO; Brown HR; Parks DJ; Plunket KD; Tong WQ; Menius JA; Adkison K; Noble SA; Willson TM
Diabetes; 1999 Jul; 48(7):1415-24. PubMed ID: 10389847
[TBL] [Abstract][Full Text] [Related]
38. Dual PPARalpha /gamma activation provides enhanced improvement of insulin sensitivity and glycemic control in ZDF rats.
Brand CL; Sturis J; Gotfredsen CF; Fleckner J; Fledelius C; Hansen BF; Andersen B; Ye JM; Sauerberg P; Wassermann K
Am J Physiol Endocrinol Metab; 2003 Apr; 284(4):E841-54. PubMed ID: 12475752
[TBL] [Abstract][Full Text] [Related]
39. 15-Deoxy-delta 12, 14-prostaglandin J2 is a ligand for the adipocyte determination factor PPAR gamma.
Forman BM; Tontonoz P; Chen J; Brun RP; Spiegelman BM; Evans RM
Cell; 1995 Dec; 83(5):803-12. PubMed ID: 8521497
[TBL] [Abstract][Full Text] [Related]
40. Structural requirements and cell-type specificity for ligand activation of peroxisome proliferator-activated receptors.
Johnson TE; Holloway MK; Vogel R; Rutledge SJ; Perkins JJ; Rodan GA; Schmidt A
J Steroid Biochem Mol Biol; 1997; 63(1-3):1-8. PubMed ID: 9449199
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
